2) Ofev (nintedanib) Ofev, a small molecule tyrosine kinase inhibitor (TKI) first approved by the FDA in 2014, is prescribed for treating idiopathic pulmonary fibrosis (IPF)
It also slows down the movement of food through the stomach and curbs appetite, thereby causing weight loss
This perspective, while understandable from a historical context, conflicts with current American Medical Association guidelines that recognize obesity as a chronic disease requiring multimodal treatment including pharmacotherapy when appropriate
Ongoing care, per Omzo's published materials, includes access to the Omzo app for tracking progress, clinician-reviewed treatment plan adjustments, and ongoing support via the platform's care team
Medication costs and lab work are not included in the membership price, but the company works with your insurance to help make them more affordable
By 2024, the associated weight loss was only half as large as the 2021 estimate, and the effect on A1C was not statistically different from zero